Chart: Council Highlights Priority Areas
This article was originally published in The Gray Sheet
You may also be interested in...
"Plug And Play" Medical Systems Raise Complicated Regulatory Questions
FDA, device makers and others are struggling to identify the best way to regulate "interoperable" medical systems - such as an iPhone that receives blood glucose data - with some suggesting that a separate classification scheme might be needed
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.